News on Amarin (NASDAQ:AMRN) has stalled recently while everyone holds their breath and waits for the Food and Drug Administration ,to decide whether to grant the company's triglyceride-lowering drug, Vascepa, new chemical entity (or NCE) status. The NCE designation would mean market exclusivity for five years, and obtaining this would also be a major driving force for the company's stock price. However, shareholders have to remember that the FDA has still not made a final decision. In this video, health care analysts Max Macaluso and David Williamson discuss the best- and worst-case scenarios for Amarin investors in the short term.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/15/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.